N6-ciklopentiladenozin
N6-ciklopentiladenozin (CPA) je lek koji deluje kao selektivni agonist adenozinskog A1 receptora.[3] On uglavnom ima kardiovaskularno dejstva sa samo suptilnim izmenama ponašanja.[4] CPA je u širokoj upotrebi u naučnim istraživanjima adenozinskog receptora i korišten je za razvoj velike familije derivata.[5][6][7][8][9]
| |
| Nazivi | |
|---|---|
| IUPAC naziv
(2R,3R,4S,5R)-2-[6-(ciklopentilamino)purin-9-il]-5-(hidroksimetil)oksolan-3,4-diol
| |
| Identifikacija | |
3D model (Jmol)
|
|
| |
| Svojstva | |
| C15H21N5O4 | |
| Molarna masa | 335,36 g·mol−1 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
 verifikuj (šta je   ?)
| |
| Reference infokutije | |
Reference уреди
- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Williams M, Braunwalder A, Erickson TJ (1986). „Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue”. Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (2): 179—83. PMID 3703020. doi:10.1007/BF00511410.
- ^ Coffin VL, Spealman RD (1987). „Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys”. The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 76—83. PMID 3572798.
- ^ Zablocki JA, Wu L, Shryock J, Belardinelli L (2004). „Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)”. Current Topics in Medicinal Chemistry. 4 (8): 839—54. PMID 15078215. doi:10.2174/1568026043450998.
- ^ Hutchinson SA, Scammells PJ (2004). „A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential”. Current Pharmaceutical Design. 10 (17): 2021—39. PMID 15279543. doi:10.2174/1381612043384204.
- ^ Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J (2007). „N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists”. Bioorganic & Medicinal Chemistry Letters. 17 (1): 161—6. PMID 17045477. doi:10.1016/j.bmcl.2006.09.065.
- ^ Elzein E, Zablocki J (2008). „A1 adenosine receptor agonists and their potential therapeutic applications”. Expert Opinion on Investigational Drugs. 17 (12): 1901—10. PMID 19012505. doi:10.1517/13543780802497284.
- ^ Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (2009). „N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice”. Journal of Medicinal Chemistry. 52 (8): 2393—406. PMID 19317449. doi:10.1021/jm801456g.
